Germany's BioNTech , whose COVID-19 vaccine in partnership with Pfizer was widely used during the pandemic, said on Monday ...
Vaccine availability is on a first-come, first-served basis and while supplies last. Updated bivalent Pfizer-BioNTech and Moderna COVID-19 vaccines and boosters will be available at the clinics. The ...
A new study shows that immunity after a COVID-19 booster lasts much longer than the primary series alone. These findings are among other, sometimes 'unintuitive,' revelations of how factors like age, ...
People who got the COVID-19 booster had stronger protection against the virus that causes the disease compared to people who ...
Pfizer-BioNTech, Moderna, Sanofi/GSK and Novavax. Those getting the spring booster will be given an mRNA vaccine made by either Pfizer or Moderna. Both have been updated to help protect against ...
COVID vaccine booster shots were rolled out, and about 40 percent of US adults said they did not plan on getting a booster.
GlaxoSmithKline sued Pfizer and BioNTech in Delaware federal court on Thursday, accusing them of infringing GSK patents ...
BioNtech-Pfizer has promised to deliver up to 75 million more coronavirus vaccine doses to the EU in the second quarter of 2021, the company's head Sierk Poetting said in a statement on Monday.
Shortly after winning a stay on a COVID-19 vaccine patent lawsuit brought by Moderna, Pfizer and its German partner BioNTech are being dragged into another round of mRNA litigation by GSK.
April 25 (Reuters) - GlaxoSmithKline sued Pfizer and BioNTech in Delaware federal court on Thursday, accusing them of infringing GSK patents related to messenger RNA (mRNA) technology in the ...
The lawsuit adds to a web of high-stakes U.S. court cases involving Pfizer, BioNTech and Moderna over patent royalties for technology used in their vaccines, including a case brought by Moderna ...
April 25 (Reuters) - GlaxoSmithKline sued Pfizer and BioNTech in Delaware federal court on Thursday, accusing them of infringing GSK patents related to messenger RNA (mRNA) technology in the companies ...